Ramasastry Saira 4

What Happened

• Saira Ramasastry, a director of Mirum Pharmaceuticals (MIRM), received two equity awards on 2026-06-15 totaling 5,752 derivative units: 3,772 and 1,980. Both were reported at a $0 acquisition price (typical for compensatory grants) and are listed as derivative awards rather than immediately issued common stock.

Key Details

• Transaction date: 2026-06-15; Form 4 filed 2026-06-17.
• Awards: 3,772 (derivative) and 1,980 restricted stock units (derivative); combined total = 5,752 units.
• Price: $0.00 per unit; total reported acquisition value $0 (compensatory grant).
• Vesting / footnotes:
  • F1: The first award vests on the first anniversary of the grant date; any referenced option will be fully vested by the Issuer's 2027 annual meeting.
  • F2: The 1,980 units are restricted stock units (RSUs), each convertible to one share, vesting on the first anniversary or fully vesting by the 2027 annual meeting.
• Shares owned following the transaction: not specified in the provided filing excerpt.
• Timeliness: Filing date (2026-06-17) covers transactions dated 2026-06-15 (no late-filing flag shown in the provided data).

Context

• These are compensatory derivative awards (RSUs and/or option-style awards) that do not immediately transfer common shares; they convert/vest later if vesting conditions are met.
• Grants at $0 are standard for director compensation and are not direct purchases or sales—so they are routine compensation, not a market sale or buy indicating immediate sentiment.